Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03696680

Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal

Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal: Phase 2 Study in 2 Steps

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
46 (estimated)
Sponsor
Centre Francois Baclesse · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases

Conditions

Interventions

TypeNameDescription
RADIATIONFSRT Stereotactic radiation therapyFor each metastasis, dose of 30 Gy in 3 fractions at 10 Gy / fraction over 7 days

Timeline

Start date
2019-01-16
Primary completion
2027-06-01
Completion
2028-01-01
First posted
2018-10-05
Last updated
2025-02-11

Locations

4 sites across 1 country: France

Source: ClinicalTrials.gov record NCT03696680. Inclusion in this directory is not an endorsement.

Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal (NCT03696680) · Clinical Trials Directory